The disintegrin and metalloproteinase ADAM15 belongs to a large family of about 40 homologous transmembrane glycoproteins that share a common modular ectodomain architecture [1, 2] . The extracellular components consist of a cysteine-rich region and a disintegrin domain, which contributes to cell-cell interactions via its capability to interact with alphav␤3, alpha5␤1 and the alpha9 integrins [3] [4] [5] 
pathology via the proteolytic shedding of membrane-bound receptor ligands in analogy to the proinflammatory effects of ADAM17 (TNFalpha converting enzyme) [reviewed in 12]. Although studies of EGF-receptor (EGFR) transsignalling in tumour cells suggest a respective potential of the ADAM15 MP domain to act as a sheddase of EGFR ligands
, corresponding evidence for a similar role in degenerative cartilage disease is entirely missing. Although the function of the ADAM15 MP domain remains enigmatic, the accelerated development of murine osteoarthritic lesions in ADAM15-deficient mice compared with wild-type rather suggests a homeostatic than a destructive role of ADAM15 in cartilage remodelling [14] . Accordingly, the more recently uncovered reinforcement of integrin-dependent collagen II (CII) adhesion by ADAM15 overexpression in the human chondrocyte cell line T/C28a4 associated with cell survival promoting effects in vitro [14] has gained importance for a better understanding of ADAM15 up-regulation in early OA cartilage. Therefore, the aim of the present study was to identify the functional domain (s) 
of ADAM15 involved in the enhanced CII binding by transfecting T/C28a4 chondrocytes with full-length ADAM15 cDNA and its respective deletion mutants and to characterize concomittant alterations of the outside-in signalling during collagen adhesion. The results of our investigation uncover the critical role of the prodomain for the capacity of ADAM15 to reinforce chondrocyte-binding to CII thereby identifying for the first time a direct function of a MP-prodomain for cell adhesion to ECM. The cytoplasmic tail of ADAM15, although dispensible for the enhanced CII adhesion, however, confers a modulatory effect on outside-in signalling during chondrocyte-matrix interaction. Thus, our results demonstrate that ADAM15 overexpression results in a reduced phosphorylation at the critical autophosphorylation site at Y397 in the non-receptor tyrosine kinase focal adhesion kinase (FAK) localized to focal adhesions.

Materials and methods
Materials
Cloning of full-length ADAM15 and deletion mutants
Full-length ADAM15 was subcloned from the previously used pcDNA vector containing the full-length sequence [14] 
Generation of permanent cell lines transfected with ADAM15 and domain deletion mutants
The transfection and selection procedures were performed as described previously [14] . Briefly, T/C28a4 chondrocytic cells were transfected in 6-well 
Cell adhesion assay
Adhesion assays were performed as described previously [15] . 
Preparation of cell lysates and Western blotting
Results
Generation of permanent cell lines expressing ADAM15 and domain deletion mutants
The multi-domain structure of ADAM15 was analysed using SMART [17, (Fig. 1B) . The polyclonal antibody with specificity for the prodomain detected only the full-length ADAM15 and the ⌬cyto at 85 kD (Fig. 1C) . The commercially available monoclonal as well as the polyclonal goat antibodies both originally raised against the entire recombinant extracellular part of human ADAM15 only detected the full-length ADAM15 and ADAM15 ⌬cyto, thus allowing for the conclusion that their epitope/s localize to the prodomain (aa . The result is shown for the monoclonal antibody (Fig. 1D) . (Fig. 2B and C) . However, the detection signal of the CII band using the antibody against the prodomain was somewhat weaker compared with the signal detected by the anti-Gst, presumably because binding of the prodomain to collagen might affect the accessibility of the anti-prodomain antibody to its epitope. In addition, binding studies of Pro-Gst were performed in 96-well plates coated with native triple helical CII using either antiprodomain or anti-Gst antibodies for detection of the bound fusion protein (Fig. 2B and C) (lanes a, b) and the corresponding immunoblot using anti-Gst antibodies  (lanes c, d). (B, C) (Fig. 4B) . (Fig. 5A) . The same set of experiments was performed on cells transfected with the ADAM15 ⌬ cyto and the
The prodomain binds to native collagen type II
. Binding of Pro-Gst was concentrationdependent and reached a plateau at 125 nM when developed with anti-Gst, or 250 nM when detected with anti-prodomain antibodies. The destruction of the triple helical conformation of CII by heat-denaturation abrogated the binding of Pro-Gst completely.
The prodomain is critical for the reinforcement of collagen adhesion by ADAM15
Chondrocytic cells overexpressing the entire ADAM15 molecule attach to CII significantly better than vector-transfected control cells [Ref. 14 and Fig. 3A]. This 2-2.5-fold enhanced binding compared with vector control also applies to chondrocytes transfected with an ADAM15 mutant lacking the complete cytoplasmic
Fig. 2 Binding of Pro-Gst fusion protein to native and denatured collagen type II (CII). (A) SDS/PAGE of the purified Pro-Gst at 49 kD and Gst-tag at 26 kD
e, g) were transferred to a nitrocellulose filter, incubated with Pro-Gst and detected with anti-Gst (B) and antiprodomain antibodies (C). Incubation with the Gst-tag alone is shown in (B, C; lanes d, e). Controls were performed without addition of Pro-Gst, but using the detection antibodies (B, C; lanes f, g). Using ELISA technique, soluble ProGst (0-250 nM) was incubated on immobilized native CII (᭹) or denatured CII () and detected with anti-Gst (B) or anti-prodomain antibodies (C). B, ᭡ incubation of the Gst-tag with native CII. Mean values and standard deviation from triplicates are shown. domain, indicating that this intracellular part is dispensible for the proadhesive effect of ADAM15 on chondrocyte interaction with CII (Fig. 3B). However, cells expressing a truncated ADAM15 mutant devoid of its prodomain lose their capability of an enhanced collagen binding. The additional deletion of the MP domain (⌬ProMP) resulted in a further impairment of CII binding of 25-30% as compared with the vector control (Fig. 3C). All transfected cells did not exhibit any statistically significant difference in their binding ability to fibronectin. No attachment to BSA was observed.
The cytoplasmic domain is involved in ADAM15-dependent signal transduction during adhesion to collagen type II
Vector-, ADAM15-and ADAM15 ⌬ cyto-transfected cells were plated on CII for 15, 30, 45 and 60 min under strict serum-free conditions and analysed for tyrosine-phosphorylated proteins by Western blot with a pan tyr-phospho antibody. Under these
Fig. 3 ADAM15 and ADAM15 ⌬cyto exhibit reinforced binding to collagen type II (CII). Cells were adhered at various densities to CII, fibronectin and BSA. (A) Shown are results of representative adhesion experiments using vector-transfected control cells (solid bar) and ADAM15-transfected cells (open bar). (B) Cells expressing only the transmembrane-anchored extracellular part of ADAM15 (⌬cyto) also show stronger binding to CII compared with the control cells. (C) Cells expressing ADAM15 without the prodomain (⌬ pro) exhibited the same binding to CII as control, and the additional removal of the MP-domain (⌬ ProMP) consistently reduced cell adhesion to about 25% below the level of vector control cells. All cells transfected with ADAM15 and the deletion constructs did not exhibit enhanced binding to fibronectin compared with the vector control cells and none of the cells exhibited binding to BSA (shown exemplarily for ADAM15-and ⌬cyto-transfected cells). Values are the mean and standard deviations of quadruplicates. adhesion conditions, the T/C28a4 chondrocytes attach very loosely to the collagen-coated wells, stay round-shaped up to 30-40 min. and start to spread very slightly after 60 min. of adhesion (not shown). Differences of staining intensities of phosphoprotein bands between vector control and the ADAM15-transfected cells were discernible very prominently in the molecular weight ranges of 120-130 kD as well as 60-80 kD (Fig. 4A). The phosphorylation pattern of the cells expressing ADAM15 without the cytoplasmic tail, however, remained unchanged compared with vector control, thus indicating an involvement of the cytoplasmic domain in the transduction of ADAM15-dependent signals during collagen adhesion
FAK is less phosphorylated at its autophosphorylation site in ADAM15-transfected cells during adhesion to CII
Fig. 5 Adhesion to CII results in a reduced phosphorylation of focal adhesion kinase (FAK) at Y397 in ADAM15 expressing cells. Cells were adhered to CII and lysed after 15, 30 and 60 min. Cell lysates (40 g) were applied to SDS/PAGE and immunoblotted using anti-pY397 FAK antibodies. (A) ADAM15 (ϩ)-transfected cells exhibit a 2-3 times reduced phosphorylation of FAK compared with vector control (Ϫ) cells, whereas (B) ADAM15 ⌬ cyto expressing cells (⌬C) show an identical activation of FAK during adhesion. As loading control, all filters were stripped and reprobed with anti-FAK antibodies and expression of ADAM15 and ADAM15
⌬ cyto was controlled using anti-ADAM15 antibodies. Optical density of the bands was analysed using ImageJ software and normalized to non-phosphorylated FAK expression. 
ADAM15 and FAK co-immunoprecipitate with each other
Based on the modulatory effect of ADAM15 on FAK phosphorylation, we further analysed the possibility of an underlying protein-protein interaction between both molecules. Accordingly, co-immunoprecipitation studies were performed on ADAM15-and vector-transfected T/C28a4 chondrocytes using ADAM15-and FAK-specific antibodies for selective protein precipitation and subsequent Western blot analyses. ADAM15 protein can be precipitated specifically only in the ADAM15 expressing cells (ϩ) using the mouse monoclonal anti-ADAM15 antibody (Fig. 6A, left panel) and accordingly, FAK co-immunoprecipitates in ADAM15-(ϩ), but not in the vector-transfected cells (-) (Fig. 6A, right panel) . Conversely, co-immunoprecipitation was also performed by capturing FAK with a specific monoclonal antibody in the first step followed by the detection of the FAK-associated ADAM15 protein in ADAM15-transfected (ϩ) only, but not in the control cells (-) (Fig. 6B,  right panel) . The anti-FAK monoclonal antibody can precipitate FAK from both vector and ADAM15-transfected cells (Fig. 6B, left  panel) . Additional experiments demonstrate that the interaction of ADAM15 with FAK is not restricted to the human cell line, but is also detectable in primary human OA chondrocytes obtained from late-stage disease (Fig. 7B) . Although FAK is expressed in normal as well as in OA chondrocytes, ADAM15 expression remains clearly confined to OA chondrocytes ( Fig. 7A and ref [9] ).
Discussion
The recently uncovered proadhesive effects of ADAM15 in chondrocyte binding to CII associated with an anti-apoptotic function [14] [19, 20] but not ADAM10 [21] . This chaperone function is even required for cell membrane expression. Although the potential role of the ADAM15-prodomain as a chaperone is unclear so far, it is however not imperative for ADAM15 cell surface expression. Thus, we could show by cell surface biotinylation that ADAM15 mutants lacking the prodomain (⌬Pro and ⌬ProMP) are expressed on the cell surface (data not shown) in accordance with the previously published data on ADAM10 [21] . Of course, the surface expressions of the ⌬Pro and ⌬ProMP constructs do not prove the lack of any chaperone function of the ADAM15 
Fig. 6 ADAM15 interacts with FAK. Co-immunoprecipitation (IP) experiments were performed in vector-(Ϫ) and ADAM15-transfected cells (ϩ) by using either anti-ADAM15 or anti-FAK antibodies for selective protein precipitation followed by immunoblotting (IB) with a polyclonal anti-ADAM15 antibody directed against the cytoplasmic tail or a monoclonal anti-FAK. (A) ADAM15 precipitates specifically with the mouse monoclonal anti-ADAM15 in the ADAM15 expressing cells only (left panel) and FAK is co-immunoprecipitated with ADAM15 (right panel). (B) Using anti-FAK antibodies, FAK is precipitated in cell lysates from vector-and ADAM15-transfected cells (left panel) and ADAM15 co-immunoprecipitates with FAK in ADAM15 expressing cells only (right panel
